Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12878044 | 0.91 | SPHK1 (0.76) | SPHK1SPHK2 | |
| SCHEMBL11997307 | 0.91 | SPHK1 (0.80) | SPHK1SPHK2 | |
| SCHEMBL11996043 | 0.88 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL11996049 | 0.88 | SPHK1 (0.81) | SPHK1SPHK2 | |
| SCHEMBL18024946 | 0.88 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL18969865 | 0.88 | SPHK1 (0.81) | SPHK1SPHK2 | |
| SCHEMBL11996046 | 0.88 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL18978675 | 0.86 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL11996041 | 0.86 | SPHK1 (1.00) | SPHK1SPHK2 | |
| SCHEMBL11996035 | 0.86 | SPHK1 (1.00) | SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908849-B2 | Imidamide sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908849-B2 | Imidamide sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170166525-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA | 2017-06-15 | — | — | US | disclosed |
| US-20170166525-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA | 2017-06-15 | — | — | US | disclosed |
| US-9421177-B2 | Imidamide sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-9421177-B2 | Imidamide sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-20120214858-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214858-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214858-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | SPHK2, SPHK1, S1PR2 | SPHK1 2/4885SPHK2 1/4885 |
| US-20170166525-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | SPHK2, SPHK1, S1PR2 | SPHK1 2/4885SPHK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.